Nordea Investment Management AB Grows Stock Holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Nordea Investment Management AB grew its stake in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 3.4% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 90,693 shares of the company’s stock after acquiring an additional 2,985 shares during the period. Nordea Investment Management AB’s holdings in Prestige Consumer Healthcare were worth $7,066,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the company. Quest Partners LLC lifted its holdings in shares of Prestige Consumer Healthcare by 2,826.7% in the 2nd quarter. Quest Partners LLC now owns 439 shares of the company’s stock worth $30,000 after buying an additional 424 shares during the period. Northwestern Mutual Wealth Management Co. grew its holdings in Prestige Consumer Healthcare by 562.3% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 510 shares of the company’s stock worth $35,000 after acquiring an additional 433 shares in the last quarter. nVerses Capital LLC raised its holdings in shares of Prestige Consumer Healthcare by 200.0% in the 3rd quarter. nVerses Capital LLC now owns 600 shares of the company’s stock valued at $43,000 after purchasing an additional 400 shares in the last quarter. Huntington National Bank boosted its stake in shares of Prestige Consumer Healthcare by 39.9% during the third quarter. Huntington National Bank now owns 635 shares of the company’s stock valued at $46,000 after purchasing an additional 181 shares in the last quarter. Finally, International Assets Investment Management LLC increased its holdings in Prestige Consumer Healthcare by 7,112.5% during the third quarter. International Assets Investment Management LLC now owns 1,154 shares of the company’s stock valued at $83,000 after buying an additional 1,138 shares during the period. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Insider Buying and Selling at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, EVP Adel Mekhail sold 9,063 shares of the business’s stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $82.00, for a total transaction of $743,166.00. Following the transaction, the executive vice president now owns 18,365 shares of the company’s stock, valued at approximately $1,505,930. The trade was a 33.04 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Mary Beth Fritz sold 9,885 shares of Prestige Consumer Healthcare stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $81.97, for a total transaction of $810,273.45. Following the transaction, the senior vice president now directly owns 18,835 shares in the company, valued at $1,543,904.95. This trade represents a 34.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 38,810 shares of company stock valued at $3,187,300 over the last ninety days. Corporate insiders own 1.60% of the company’s stock.

Prestige Consumer Healthcare Stock Up 0.9 %

Shares of PBH opened at $74.45 on Friday. The company has a market capitalization of $3.68 billion, a price-to-earnings ratio of 18.11, a PEG ratio of 2.32 and a beta of 0.51. Prestige Consumer Healthcare Inc. has a 52 week low of $58.22 and a 52 week high of $86.36. The stock’s 50-day moving average price is $80.56 and its 200-day moving average price is $74.17. The company has a quick ratio of 2.10, a current ratio of 3.56 and a debt-to-equity ratio of 0.61.

Prestige Consumer Healthcare (NYSE:PBH) last posted its earnings results on Thursday, November 7th. The company reported $1.09 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.09. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. The business had revenue of $283.79 million for the quarter, compared to analyst estimates of $282.09 million. During the same period in the prior year, the company posted $1.07 EPS. The company’s revenue for the quarter was down .9% on a year-over-year basis. On average, sell-side analysts predict that Prestige Consumer Healthcare Inc. will post 4.44 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have recently commented on PBH shares. DA Davidson reissued a “buy” rating and issued a $95.00 price target on shares of Prestige Consumer Healthcare in a research report on Monday, November 11th. StockNews.com upgraded shares of Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a research note on Tuesday. Sidoti downgraded shares of Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 target price for the company. in a research note on Monday, December 9th. Jefferies Financial Group reiterated a “hold” rating and set a $76.00 price objective (up previously from $70.00) on shares of Prestige Consumer Healthcare in a report on Tuesday, September 24th. Finally, Raymond James raised Prestige Consumer Healthcare to a “moderate buy” rating in a research report on Thursday, December 19th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $85.25.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.